It seems hardly any of the new patients were assessable.
It will be interesting to see if they have enough data for a shot at phase 2 being approved as a registrational study.
Don't see any reference to it. Though it seems that there has been a tempering of over exuberantly forward looking statements.
Still it looks like a marked improvement on SOC.
I personally prefer the more reality balanced and fact based communication style. Let the data talk and leave the supposition to oneself.
Ann: PTX-100 Ph1b results show excellent safety & efficacy in TCL, page-20
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
